2024 annual financial data
TScan Therapeutics 2024 Net margin
Direct answer
Net margin was -4,527.66%.
Operating income was -134.82M USD and net income was -127.5M USD.
Operating cash flow was -110.82M USD.
Get free TScan Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 2.82M USD
- Operating income
- -134.82M USD
- Net income
- -127.5M USD
- Operating cash flow
- -110.82M USD